

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RDID 02010 US

In Re Application Of: **Ghoshal et al.**

Serial No.

TBA

Filing Date

December 10, 2003

Examiner

TBA

Group Art Unit

TBA

Title: **Reagents for Detecting Efavirenz**

Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
 - the statement specified in 37 CFR 1.97(e);

OR

- the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RDID 02010 US

In Re Application: **Ghoshal et al.**

Serial No.

TBA

Filing Date

December 10, 2003

Examiner

TBA

Group Art Unit

TBA

Reagents for Detecting Efavirenz

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of _____ is attached.

The Director is hereby authorized to charge and credit Deposit Account **02-2958** as described below.

Charge the amount of _____

Credit any overpayment.

Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F: _____)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on ~~December 10, 2003~~ ^{EX-2003} with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Marsha S. Breen

Signature of Person Mailing Correspondence

Marsha S. Breen by Express Mail EV 288801582 US

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Marilyn Amick
Signature

Dated: *Dec. 10, 2003*

CC:

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Docket Number (Optional) RDID 02010 US			Application Number TBD		
		Applicants(s) Ghoshal et al.					
		Filing Date December 10, 2003			Group Art Unit		
U.S. PATENT DOCUMENTS							
Examiner Initials	Ref	Document Number	Date	Name	Class	Subclass	Filing Date (If Appropriate)
		5,633,405	5/27/97	Thompson et al.	564	321	
FOREIGN PATENT DOCUMENTS							
	Ref	Document Number	Date	Country	Class	Subclass	Translation
Other Documents (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Mutlib et al. "Identification and Characterization of Efavirenz Metabolites by Liquid Chromatography/Mass Spectrometry and High Field NMR: Species Differences in the Metabolism of Efavirenz". <i>Drug Metabolism and Disposition</i> , Vol 27, No. 11, pg 1319-1333					
		Marzolini et al., "Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients". <i>AIDS</i> 2001, 15: 71-75					
		Singh et al., "Cesium Fluoride Catalyzed Trifluoromethylation of Esters, Aldehydes, and Ketones with (Trifluoromethyl) Trimethylsilane", <i>J. Org Chem</i> 1999, 64, 2873-2876					
		Radesca, et al., "Synthesis of HIV-1 Reverse Transcriptase Inhibitor DMP 266", <i>Synthetic Communications</i> , 27(24), 4373-4384 (1997)					
		Zhuyin Li et al., "New Synthesis and Characterization of (+) Lysergic Acid Diethylamide (LSD) Derivatives and the Development of a Microparticle-Based Immunoassay for the Detection of LSD and Its Metabolites", <i>Bioconjugate Chem.</i> 1997, 8, 896-905					
		Prakash, G.K., Yudin AK, "Perfluoroalkylation with Organosilicon Reagents", <i>Chem Rev</i> 1997, 97, 757-786					
		Patel, et al., "Synthesis and Evaluation of Analogs of Efavirenz (Sustiva™) as HIV-1 Reverse Transcriptase Inhibitors", <i>Bioorganic & Medicinal Chemistry Letters</i> 9 (1999), 2805-2810					
Examiner				Date Considered			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							